Table IV.

The correlation between serum levels of CEA, CA19-9, CA72-4 in patients with gastric carcinoma in different clinicopathological features.

		CEA vs. CA19-9		CEA vs. CA72-4		CA19-9 vs. CA72-4
ClinPath feature	N	Coef	P-value	Coef	P-value	Coef	P-value
Gender
Male	172	0.217	0.004	0.266	0.000	0.065	0.399
Female	44	0.376	0.012	0.330	0.029	0.465	0.002
Age
≤60 years	93	0.186	0.075	0.238	0.022	0.299	0.004
>60 years	123	0.263	0.003	0.313	0.000	0.060	0.513
Histology
Differ	52	0.285	0.041	0.342	0.013	0.018	0.901
Undiffer	164	0.213	0.006	0.266	0.001	0.211	0.007
T-stage
T1–2	53	0.219	0.116	0.153	0.274	−0.020	0.889
T3–4	140	0.255	0.002	0.294	0.000	0.162	0.056
N-stage
N(−)	71	0.207	0.083	0.112	0.354	−0.057	0.640
N(+)	116	0.267	0.004	0.347	0.000	0.300	0.001
M-stage
M0	193	0.251	0.000	0.255	0.000	0.174	0.015
M1	23	0.022	0.920	0.261	0.229	0.089	0.688
TNM-stage
I/II	100	0.211	0.036	0.297	0.002	−0.046	0.646
III/IV	116	0.234	0.011	0.288	0.001	0.239	0.010
Total cases	216	0.231	0.001	−0.271	<.0001	0.167	0.014

Coef, Spearman's correlation coefficient; ClinPath, clinicopathological; Diff, differentiated; Undiff, undifferentiated; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; CA72-4, carbohydrate antigen 72-4.